Cargando…
Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma
Drug resistance causes therapeutic failure in refractory cancer. Cancer drug resistance stems from various factors, such as patient heterogeneity and genetic alterations in somatic cancer cells, including those from identical tissues. Generally, resistance is intrinsic for cancers; however, cancer r...
Autores principales: | Lim, Jin Hong, Park, Keunwan, Choi, Kyung Hwa, Kim, Chan Wung, Lee, Jae Ha, Weicker, Raymond, Pan, Cheol-Ho, Kim, Seok-Mo, Park, Ki Cheong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322808/ https://www.ncbi.nlm.nih.gov/pubmed/35887321 http://dx.doi.org/10.3390/ijms23147971 |
Ejemplares similares
-
Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2022) -
Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
por: Kim, Yuna, et al.
Publicado: (2023) -
Machine learning-based chemical binding similarity using evolutionary relationships of target genes
por: Park, Keunwan, et al.
Publicado: (2019) -
Identification of Tyrosinase Inhibitors and Their Structure-Activity Relationships via Evolutionary Chemical Binding Similarity and Structure-Based Methods
por: Durai, Prasannavenkatesh, et al.
Publicado: (2021) -
Evolutionary chemical binding similarity approach integrated with 3D-QSAR method for effective virtual screening
por: Durai, Prasannavenkatesh, et al.
Publicado: (2020)